[아이뉴스24 정종오 기자] Ovarian cancer, known as a gynecological malignancy with recurrence and high mortality in over 80%. In the case of recurrence, there are many cases that do not respond to chemotherapy. Therefore, ovarian cancer is very difficult to treat. In the midst of this, a domestic research team has proposed a new treatment method using bioplasma.
A team led by Professors Kwon Byung-soo and Jeong Min-hyung of Kyung Hee University Hospital’s Department of Obstetrics and Gynecology drew attention by presenting a new peritoneal chemotherapy strategy for ovarian cancer.
A research team led by Professors Kwon Byung-soo and Jeong Min-hyung conducted a study to examine the potential and effects of bioplasma in the treatment of ovarian cancer.
Although various new drugs such as targeted therapies and immunotherapy are being developed for ovarian cancer, more than 80% of patients experience recurrence. In particular, there are many cases of non-responsiveness to chemotherapy after relapse. It is considered one of the most common gynecological malignancies with the highest mortality rate worldwide.
Professor Kwon Byung-soo said, “The reason for the fatal recurrence rate and treatment resistance is that cancer cells with stem cell properties are involved in anticancer drug resistance, recurrence, and metastasis. We looked at the effect on ovarian cancer treatment using plasma activated water, which is known to be effective.”
Recently, a method of directly injecting an anticancer agent into the abdominal cavity to increase the anticancer treatment effect has also been attempted. The research team has been conducting research for several years to reduce the occurrence of anticancer drug resistance while improving the therapeutic effect of anticancer drugs using plasma in the treatment of intraperitoneal anticancer drug administration.
As a result, when treated with plasma-activated water, it showed a dose-dependent inhibitory effect and a significant result was shown in reducing the expression of stem cell markers.
Professor Kwon said, “In addition, we confirmed that bioplasma improved the cytotoxicity of cisplatin, which is widely used as an anticancer drug for ovarian cancer, without side effects. It will be of great significance in that it has confirmed its potential as a new therapeutic agent.”
The research results were published in Free Radical Biology and Medicine, an SCI-level international academic journal.
/Reporter Jeong Jong-oh([email protected])<!–
–>